Relationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein sub-fractions: a post-hoc analysis of the PIVENS trial
| Autor: | Corey, Kathleen E, Wilson, Laura A, Altinbas, Akif, Yates, Katherine P, Kleiner, David E, Chung, Raymond T, Krauss, Ronald M, Chalasani, Naga, NASH Clinical Research Network |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male Lipoproteins Biopsy Clinical Trials and Supportive Activities Chronic Liver Disease and Cirrhosis Clinical Sciences Vascular Cell Adhesion Molecule-1 Cardiovascular Hepatitis Non-alcoholic Fatty Liver Disease Clinical Research NASH Clinical Research Network Humans Vitamin E Particle Size Retrospective Studies Dyslipidemias Nutrition Pioglitazone Gastroenterology & Hepatology Liver Disease Remission Induction Evaluation of treatments and therapeutic interventions Pharmacology and Pharmaceutical Sciences Macrophage Activation Middle Aged Intercellular Adhesion Molecule-1 Treatment Outcome 6.1 Pharmaceuticals Female E-Selectin Digestive Diseases Biomarkers |
| Zdroj: | Alimentary pharmacology & therapeutics, vol 49, iss 9 |
| Popis: | BackgroundDyslipidaemia is frequent in non-alcoholic steatohepatitis (NASH); however, it is unclear if improvement in liver histology is associated with favourable changes in cardiovascular disease (CVD) risk.AimsTo evaluate the relationship of NASH resolution and lipoprotein subfraction levels, markers of endothelial dysfunction, and macrophage activation.MethodsOne hundred and seventeen individuals with NASH who participated in the Pioglitazone vs Vitamin E vs Placebo for the Treatment of Nondiabetic Patients with NASH (PIVENS) trial with paired liver biopsies and serum samples available at baseline and after 96weeks of treatment were included. Participants in the PIVENS trials received vitamin E, pioglitazone, or placebo for 96weeks. Lipoprotein subfraction levels, intracellular adhesion molecule 1 (ICAM-1), vascular cellular adhesion molecule 1 (VCAM-1), E-selectin, and sCD163 levels were assessed at baseline and week 96 and their relationship with NASH resolution was examined.ResultsFifty-seven individuals had NASH resolution and 60 individuals did not have resolution of NASH. NASH resolution was associated with favourable changes in lipoprotein subfraction levels compared to those without NASH resolution. Individuals with resolution of NASH had a significantly increased mean peak LDL diameter (ratio of geometric means [96weeks vs baseline] 1.007 vs 0.996, P=0.004), and higher frequency of LDL phenotype A (58% vs 33%, P=0.003) at week 96, after adjustment for relevant co-variates including treatment group. No differences in VCAM, ICAM, E-selectin, or sCD163 levels by NASH resolution were found.ConclusionsNASH resolution is associated with favourable changes in a subset of serum lipoprotein levels. More studies are warranted to understand if these favourable changes are associated with decreased risk of CVD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|